Ernest Jucker – författare
Visar alla böcker från författaren Ernest Jucker. Handla med fri frakt och snabb leverans.
9 produkter
9 produkter
881 kr
Skickas inom 10-15 vardagar
This series was founded in 1959, and its focus has shifted from medicinal chemistry to a much wider scope. It now encompasses all fields concerned with the development of therapeutic drugs and the elucidation of their mechanisms of action, reflecting the increasingly complex nature of modern drugs research. Invited authors write reviews on the following fields: biology, chemistry, biochemistry, physiology, immunology, pharmacy, toxicology, pharmacology, and clinical aspects. The books are linked by indexes in each volume, forming an almost encyclopaedic work.
881 kr
Skickas inom 10-15 vardagar
This volume contains reviews on a wide spectrum of topical areas in pharmacological and pharmaceutical research.
881 kr
Skickas inom 10-15 vardagar
Including details of current advances in drug research, this volume includes contributions by P.N. Kaul, M. Rohmer, T.D. Johnson, and R.W. Rockhold.
881 kr
Skickas inom 10-15 vardagar
881 kr
Skickas inom 10-15 vardagar
This text is part of a series which provides expert written reviews on a spectrum of areas in pharmaceutical and pharmacological research. Each volume contains fully cross-referencing indexes which link the books together, forming an encyclopaedic work.
881 kr
Skickas inom 10-15 vardagar
This volume covers a range of topics including caco-2 cell permeability versus human gastrointestinal absorption - QSPR analysis; pharmacology of appetite supression; serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors; neuropeptides in drug research; regulation of NMDA receptors by ethanol; and troglitazone and emerging glitazones - new avenues for potential therapeutic benefits beyond glycemic control and applications of developmental biology to medicine and agriculture.
881 kr
Skickas inom 10-15 vardagar
881 kr
Skickas inom 10-15 vardagar
This text provides extensive expert-written reviews on a wide spectrum of topical areas in pharmaceutical and pharmacological research.
553 kr
Skickas inom 10-15 vardagar
In the treatment of infections caused by rapidly mutating viruses like human immunodeficiency virus (HIV), combination therapy with multiple drugs act- ing by different mechanisms offers several advantages over monotherapy. It may provide: synergistic effect, possible reduction of dosages and side-effects, and reduction of the chance of drug resistance. In the past few years, hun- dreds of HIV protease inhibitors have been synthesized and tested in order to overcome the limitations of reverse transcriptase inhibitors like zidovudine and others. In this review, emphasis is placed on the development of HIV pro- tease inhibitors as antiviral agents against HIY, and structure-activity rela- tionship analysis of saquinavir and related compounds. Limitations of some protease inhibitors and ways to overcome the shortcomings are presented. Among these many protease inhibitors five have been marketed during 1995-1999. They are saquinavir, ritonavir, indinavir, nelfinavir and ampre- navir. Their different structural features, important physicochemical, phar- macokinetic and clinical profiles are presented in a table form for easy com- parison.It is hoped that in the future new drugs based on additional mech- anisms can be developed for the treatment of AIDS. Contents 4 1 Introduction ...HIV protease as a target for chemotherapy ...2 5 Design of protease inhibitors ...3 5 Basis of rational design of HIV protease inhibitors ...3.1 5 New development of HIV protease inhibitors ...6 3.2 HIV protease inhibitors on the market ...20 4 20 4.1 SAR of saquinavir and related compounds ...